BPS 2022

Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. Identification of the 3D conformational ensemble of solnatide by crystallography and NMR

Bernhard Fischer

CEO, APEPTICO

ABSTRACT

Solnatide is a 17-residue synthetic peptide and has been designed on the lectin-like domain of TNF-alpha. Various derivatives of solnatide have been proposed and chemically synthesized. Solnatide peptide is stabilized by extra intra-molecular disulfide bonds. Solnatide peptides demonstrated to activate ENaC in several experimental models of lung oedema, ischemia reperfusion injury (IRI), high altitude pulmonary oedema (HAPE), pseudohypoaldosteronism (PHA), acute respiratory distress syndrome (ARDS) and primary graft dysfunction (PGD) following lung transplantation. Today, solnatide is manufactured by solid-phase chemistry at kg-scale for the structural & molecular characterisation, as well clinical development and specification settings.
Solnatide is administered as a peptide-aerosol directly into the pulmonary airspace of patients with severe lung dysfunction.
In 2021 and 2022 during the new coronavirus pandemic, solnatide has been applied for the therapeutic treatment of both patients with moderate-severe ARDS and mechanically ventilated COVID-19 patients in clinical studies as well within national compassionate use programs.
We compare basic characteristics of ARDS patients vs. COVID-19 patients, discuss limitation in hospital management during the pandemics, as well present preliminary clinical outcome data.
We also report the molecular structure and interaction between solnatide and the pulmonary ENaC channel based on the conformational ensemble displayed by the peptide as generated through the combination of the crystallography and NMR. Analysis of the conformational ensembles displayed by solnatide shows that the peptide recaptulates structural features previously identified as relevant for the ENaC-activating effect of the lectine-like domain of TNF, namely the critical role of a triad of residues in solnatide, a hydrophobic region comprising thress consecutive residues, and the presence of a charged dipol. The middle region of solnatide, is ordered, shows H-bonding capacity, and adopts a backbone confirmation similar to that of the native protein.
The structural coordinates of solnatide will be uploaded to the PDB Protein Data Bank.

BIO

Professor Dr. Bernhard Fischer is a biotechnology expert and entrepreneurial pharma manager with long standing record in international life science biotechnology and pharmaceutical companies. In the course of his career he headed senior management positions in biopharmaceutical research and development, regulatory affairs, chemistry manufacturing & controls documentation and technical drug development.
In the course of his career he headed senior management positions in biopharmaceutical research and development, regulatory affairs, chemistry manufacturing & controls documentation and technical drug development. During his professional development he was research biochemist at the Institute of Molecular Biology and Institute of Biotechnology in Germany, Higher Scientific Officer at the Department of Protein Engineering of the AFRC in the United Kingdom, Head of the Department of Recombinant Proteins at the Biomedical Research Center of Baxter in Austria, Manager Chemistry Manufacturing & Controls and Manager Regulatory Affairs at Sandoz (Novartis) in Austria, Chief Technical Officer at Avidis in France, Vice President Development and Chief Technical Officer at Fibrex Medical in Austria.
Currently, Dr. Fischer serves as founder and CEO of APEPTICO a biotechnology start-up company developing protein and peptide based drugs.
Dr. Fischer is Lecturer for Protein Chemistry and Biomedicinal Drug Development and Regulatory Affairs at various Universities and Business Schools.

Information for BPS Presenters

The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.

Information for BPS Presenters

The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.

The Boulder Peptide Symposium offers multiple opportunities for participants to present.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.

Refund Policy - Terms and Conditions - Privacy Policy